Dr. Edward H. Bedrossian Jr., MD

Dr. Bedrossian practices at Wills Eye Hospital in Philadelphia, Pennsylvania, part of City Trusts.

Dr. Bedrossian's NPI, 1841283488, was assigned on August 30, 2005. Dr. Bedrossian graduated from Lewis Katz School of Medicine in 1978. Dr. Bedrossian holds Pennsylvania license MD024721E.

Dr. Bedrossian's primary practice is Wills Eye Hospital, at 840 Walnut Street, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 440-3150.

Dr. Bedrossian's primary practice is Wills Eye Hospital in Philadelphia, Pennsylvania, part of City Trusts. Dr. Bedrossian is also affiliated with Riddle Hospital. Dmand AI also links Dr. Bedrossian to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bedrossian practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Bedrossian's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Bedrossian is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Bedrossian's licenses on file in 3 states: Pennsylvania, New Jersey and New York.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eyelid inflammation and glaucoma among the conditions Dr. Bedrossian treats.

CMS data shows 998 Medicare services from Dr. Bedrossian across 12 procedure codes in 2024, for 161 Medicare patients. Medicare paid $50,510 for them. Every service was in an office.

CMS counts 161 Medicare patients who saw Dr. Bedrossian in 2024. The largest group is 75 to 84, with 67 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bedrossian's median patient age at 72, with 64% women.

In 2024, Dr. Bedrossian wrote 299 Medicare Part D claims for 73 patients. 77% of them were for generic drugs. CMS names the drug for 195 of them, across 6 drugs with 11 or more claims each, at $6,232 in total drug cost. In 2023, CMS named 228 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Bedrossian for performance year 2024, reported as part of a group. CMS counts 13 procedures of cataract surgery by Dr. Bedrossian, more than 36% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Bedrossian, published from 2013 to 2016. The most frequent topics are Tomography, X-Ray Computed, Eyelid Diseases and Lacrimal Apparatus Diseases. Dr. Bedrossian has published most often in Ophthalmic Plast Reconstr Surg. Dr. Bedrossian's most frequent co-authors are Michael Paul Rabinowitz, MD, Alok S. Bansal, MD and Kimberly P. Cockerham, MD.

CMS Open Payments shows 78 general payments to Dr. Bedrossian from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Horizon Pharma plc paid the most, $43,529.

Dmand AI lists 3 awards for Dr. Bedrossian.

Dr. Bedrossian graduated from Lewis Katz School of Medicine in 1978. Dr. Bedrossian is a member of AAO, ACS, American Society ofIOphthalmic Plastic and Reconstructive Surgery and Pennsylvania Academy of Ophthalmology.

Dr. Bedrossian is in network with 19 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.